The Editor of the American Journal of Therapeutics hereby issues an Expression of Concern for Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Am J Ther. 2021;28(4): e434-e460.

The decision is based on the evaluation of allegations of inaccurate data collection and/or reporting in at least 2 primary sources of the meta-analysis performed by Mr. Andrew Bryant and his collaborators.1,2 These allegations were first made after the publication of this article. The exclusion of the suspicious data appears to invalidate the findings regarding the ivermectin's potential to decrease the mortality of COVID-19 infection.2 The investigation of these allegations is incomplete and inconclusive at this time.

This Expression of Concern does not imply that the methodology used by Mr. Andrew Bryant and his collaborators was incorrect. The use of summary data published by others is a generally accepted approach in biomedical metanalytic research.1

The American Journal of Therapeutics is steadfastly committed to upholding truth in science and the highest standards in publication ethics. We will update our decision regarding this work should more information become available.

1. Lawrence JM, Meyerowitz-Katz G, Heathers JA, et al. The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable. Nat Med. 2021;27:1853–1854. 2. Rothrock SG, Weber KD, Giordano PA, et al. Meta-Analyses do not establish improved mortality with ivermectin use in COVID-19. Am J Ther. 2022;29:e87–e94.